A novel homozygous mutation in CIITA resulting in MHC Class II deficiency in an adult patient

J. Hsieh, Amarilla B. Mandola, S. Betschel
{"title":"A novel homozygous mutation in CIITA resulting in MHC Class II deficiency in an adult patient","authors":"J. Hsieh, Amarilla B. Mandola, S. Betschel","doi":"10.14785/LYMPHOSIGN-2018-0015","DOIUrl":null,"url":null,"abstract":"Introduction: Major histocompatibility (MHC) class II deficiency is a rare autosomal recessive primary immunodeficiency with fewer than 200 patients reported worldwide. Patients usually present within their first year of life with severe and recurrent infections, failure to thrive, and chronic diarrhea. The disorder is caused by absent or reduced MHC class II expression on cell surfaces, leading to defective cellular and humoral immune responses. The disease is associated with a poor prognosis, with most patients dying in early childhood due to infectious complications. Aim: To report the clinical, immunological, and genetic features of an adult patient with MHC class II deficiency who did not undergo hematopoietic stem cell transplant (HSCT). We also explore proposed theories as to why some patients with MHC class II deficiency survive to adulthood, beyond the typical life expectancy. Results: We present a 23-year-old gentleman who was diagnosed with MHC class II deficiency at the age of 6 months based on a near complete absence of Human Leukocyte Antigen - DR isotype on peripheral blood mononuclear cells and CD4+ lymphopenia. He is one of a few patients with the condition reported in the literature to have survived to adulthood despite not having undergone HSCT. Next generation sequencing revealed a novel homozygous mutation in the CIITA gene, 1 of 4 genes involved in the regulation of MHC class II transcription. Discussion: MHC class II deficiency is considered a single entity phenotypic condition where the main problem lies in reduced or absent MHC class II expression and results in downstream immunologic effects, including CD4+ lymphopenia and impaired antigen specific responses. However, phenotypic differences between patients are emerging as more cases are described in the literature. Our patient, now 23 years old, has survived significantly beyond life expectancy despite not having HSCT. Statement of novelty: We describe a case of an adult patient diagnosed with MHC class II deficiency due to a novel homozygous intronic splice site variant in the CIITA gene.","PeriodicalId":53881,"journal":{"name":"LymphoSign Journal-The Journal of Inherited Immune Disorders","volume":" ","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"LymphoSign Journal-The Journal of Inherited Immune Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14785/LYMPHOSIGN-2018-0015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

Introduction: Major histocompatibility (MHC) class II deficiency is a rare autosomal recessive primary immunodeficiency with fewer than 200 patients reported worldwide. Patients usually present within their first year of life with severe and recurrent infections, failure to thrive, and chronic diarrhea. The disorder is caused by absent or reduced MHC class II expression on cell surfaces, leading to defective cellular and humoral immune responses. The disease is associated with a poor prognosis, with most patients dying in early childhood due to infectious complications. Aim: To report the clinical, immunological, and genetic features of an adult patient with MHC class II deficiency who did not undergo hematopoietic stem cell transplant (HSCT). We also explore proposed theories as to why some patients with MHC class II deficiency survive to adulthood, beyond the typical life expectancy. Results: We present a 23-year-old gentleman who was diagnosed with MHC class II deficiency at the age of 6 months based on a near complete absence of Human Leukocyte Antigen - DR isotype on peripheral blood mononuclear cells and CD4+ lymphopenia. He is one of a few patients with the condition reported in the literature to have survived to adulthood despite not having undergone HSCT. Next generation sequencing revealed a novel homozygous mutation in the CIITA gene, 1 of 4 genes involved in the regulation of MHC class II transcription. Discussion: MHC class II deficiency is considered a single entity phenotypic condition where the main problem lies in reduced or absent MHC class II expression and results in downstream immunologic effects, including CD4+ lymphopenia and impaired antigen specific responses. However, phenotypic differences between patients are emerging as more cases are described in the literature. Our patient, now 23 years old, has survived significantly beyond life expectancy despite not having HSCT. Statement of novelty: We describe a case of an adult patient diagnosed with MHC class II deficiency due to a novel homozygous intronic splice site variant in the CIITA gene.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
CIITA中一种新的纯合突变导致一名成年患者MHC II类缺陷
主要组织相容性(MHC) II类缺陷是一种罕见的常染色体隐性原发性免疫缺陷,全世界报道的病例不到200例。患者通常在出生后一年内出现严重和反复感染、发育不良和慢性腹泻。这种疾病是由细胞表面MHC II类表达缺失或减少引起的,导致细胞和体液免疫反应缺陷。该病预后不良,大多数患者因感染性并发症在儿童早期死亡。目的:报告一名未接受造血干细胞移植(HSCT)的MHC II类缺乏成年患者的临床、免疫学和遗传学特征。我们还探讨了关于为什么一些MHC II类缺乏症患者存活到成年期的理论,超出了典型的预期寿命。结果:我们报告了一位23岁的男士,他在6个月大时被诊断为MHC II类缺乏,基于外周血单核细胞几乎完全缺乏人白细胞抗原- DR同种型和CD4+淋巴细胞减少。他是文献中报道的少数没有接受造血干细胞移植却存活到成年的患者之一。下一代测序揭示了CIITA基因的一个新的纯合突变,CIITA基因是参与MHC II类转录调控的4个基因中的一个。讨论:MHC II类缺陷被认为是一种单一实体表型病症,主要问题在于MHC II类表达减少或缺失,并导致下游免疫效应,包括CD4+淋巴细胞减少和抗原特异性反应受损。然而,随着文献中越来越多的病例描述,患者之间的表型差异正在出现。我们的病人,现年23岁,尽管没有接受造血干细胞移植,但他的存活时间大大超过了预期寿命。新颖性声明:我们描述了一例成年患者诊断为MHC II类缺陷,由于CIITA基因的一个新的纯合内含子剪接位点变异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
12.50%
发文量
12
期刊最新文献
Abstracts of the Immunodeficiency Canada 10th PID Symposium, 19 October 2023, Ottawa Neurodevelopmental disorder and immunodeficiency Novel heterozygous mutation in NFKB2 in a patient with predominantly antibody deficiency Perspectives of women in science: data sharing in primary immunodeficiency Management of newborn screening for severe combined immunodeficiency at a quaternary referral centre – an updated algorithm
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1